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Introduction
Multiple myeloma is a plasma cell malignancy character-
ized by osteolytic lesions, anemia, hypercalcemia and renal
failure.1 Several population-based studies have shown that
overall survival of patients with multiple myeloma has
improved since the introduction of novel agents such as the
immunomodulatory drugs (IMiDs) thalidomide and lenalido-
mide, bortezomib, as well as high-dose melphalan with stem
cell transplantation.2-5 However, during the same time period,
venous thromboembolism (VTE) has been increasingly
observed in patients with multiple myeloma, primarily those
who were treated with thalidomide and lenalidomide, in
combination with dexamethasone and/or combination
chemotherapy.6-8 Recently, we showed that the risk of VTE
and arterial thrombosis is increased in multiple myeloma as
well as its precursor state monoclonal gammopathy of unde-
termined significance (MGUS), suggesting that non-treatment
related factors play a role in the development of VTE in plas-
ma cell disorders.9-10 In further support of this observation,
compared to the general population, we observed a signifi-
cantly higher risk of VTE in multiple myeloma patients
before the introduction of the novel agents.9-10
In the general population, the occurrence of VTE is associat-
ed with a decrease in survival.11 Three studies have addressed
the impact of VTE in relation to survival in multiple myeloma.
In the first study, a retrospective analysis of data from a clinical
trial including 668 newly diagnosed patients treated with or
without thalidomide, survival was similar among patients who
developed VTE compared to those who did not.12 In the second
study, also a retrospective analysis of a clinical trial including
353 relapsed/refractory multiple myeloma patients treated
with lenalidomide, there was again no difference in survival in
relation to thromboembolic episodes.13 Lastly, in a retrospec-
tive analysis including 535 multiple myeloma patients treated
with thalidomide combined with cytotoxic chemotherapy
treated in different clinical trials, development of a deep vein
thrombosis (DVT) was not associated with poorer survival.14 
We conducted the first population-based study designed to
evaluate whether thrombosis influences survival in multiple
myeloma. In the largest study to date, using high-quality data
from Sweden, we assessed the impact of both venous and arte-
rial thrombosis on survival in almost 10,000 multiple myeloma
patients.
Design and Methods
The details of the study population have been described previous-
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Patients with multiple myeloma are at an increased risk of
venous thromboembolism and arterial thrombosis. We
assessed the impact of venous and arterial thrombosis on sur-
vival in a population-based study of 9,399 multiple myeloma
patients diagnosed in Sweden from 1987 to 2005. We found
multiple myeloma patients with venous thromboembolism to
have a higher mortality at 1-, 5-, and 10-years of follow up com-
pared with those without, with hazard ratios of 2.9 (95% con-
fidence interval (CI) 2.4-3.5), 1.6 (95% CI: 1.5-1.8), and 1.6
(95% CI: 1.4-1.7), respectively. There was an increase in risk of
death among multiple myeloma patients with arterial throm-
bosis, with hazard ratios of 3.4 (95% CI: 3.0-3.8), 2.2 (95% CI:
2.0-2.3), and 2.1 (95% CI: 1.9-2.1), respectively. In landmark
analyses at six months, early arterial but not venous throm-
boembolism was associated with a higher risk of death. Thus,
in contrast to prior smaller studies, we found the development
of thrombosis to be associated with significantly poorer sur-
vival. The prevention of thrombosis in multiple myeloma is an
important goal in the management of these patients.
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ABSTRACT
ly.10 All physicians and pathologists/cytologists in Sweden are
obliged by law to report each case of cancer they diagnose or treat
to the centralized nationwide Swedish Cancer Registry, which has
a very high diagnostic accuracy and completeness.15 Using the
Swedish Cancer Registry, we identified all multiple myeloma
patients diagnosed between 1987 and 2005.
The centralized Swedish Patient Registry captures information
on individual patient-based discharge diagnoses and discharge list-
ings from inpatient (since 1964) and outpatient (since 2000) care,
with a very high coverage. Information on occurrence and date of
arterial (coronary artery disease and cerebrovascular disease) and
VTE (DVT and pulmonary embolism) was obtained. All condi-
tions were analyzed both individually and grouped into cate-
gories. Through linkage with the Cause of Death Register and the
Register of Total Population, we collected information on vital sta-
tus until 31st December 2006. From the Swedish Medical Products
Agency, we gathered information on the number of patients who
were prescribed thalidomide and lenalidomide in Sweden during
the study period. 
This study was approved by the Karolinska Institutional
Review Board.
Statistical analysis
To assess the impact of thrombosis on overall survival, we treat-
ed thrombosis as a time dependent covariate in Cox’s proportional
hazard models and computed hazard ratios (HRs) and 95% confi-
dence intervals (CIs) for association (PROC PHREG, SAS, version
9.1; SAS Institute). Follow-up time started at the later of diagnosis
of multiple myeloma or 1st January 1987. The delayed entry was
accommodated by the entry time option in PROC PHREG. Follow
up ended at time of death or at time of censoring. Censoring
events were emigration, and the end of the data acquisition period
(31st December 2006). We analyzed 1-, 5-, and 10-year overall sur-
vival. We estimated HRs for any thrombosis, and also estimated
separate effects by grouping them according to arterial thrombosis
and VTE. Models were adjusted for age at diagnosis, sex and year
of diagnosis. Models were stratified by sex and by year of multiple
myeloma diagnosis (before or after 2000). P values for interaction
are based on Wald tests. 
We also performed landmark analyses in which follow up start-
ed six months after diagnosis, and assessed the impact of any
thrombotic event during the first six months on overall survival.
Thrombotic episodes that were diagnosed after the first six
months were not considered in this analysis.
Results and Discussion
A total of 9,399 multiple myeloma patients were diag-
nosed in Sweden from 1987 to 2005. The median age at
diagnosis was 71 years, with almost equal sex distribu-
tion. A total of 1,756 patients (mostly multiple myeloma)
received thalidomide in Sweden from 2000 to 2005 com-
pared to fewer than 100 before the year 2000.
Lenalidomide was prescribed to 103 patients (mostly mul-
tiple myeloma) from 2003 to 2005. A total of 724 multiple
myeloma patients developed VTE and 1,572 arterial
thrombosis during follow up.
Thrombosis and risk of death
Multiple myeloma patients with any thrombosis after
diagnosis had higher mortality rates compared to those
without, at 1-, 5-, and 10-year follow up, with HR of 3.4
(95% CI: 3.0-3.8), HR 2.1 (95% CI: 2.0-2.2), and HR 2.0
(95% CI: 1.9-2.2), respectively (Table 1). The risk of death
during the 1-, 5-, and 10-year follow up was significantly
higher with diagnosis of any VTE, HR 2.9 (95% CI: 2.4-
3.5), 1.6 (95% CI: 1.5-1.8), and 1.6 (95% CI: 1.4-1.7),
respectively, as well as with arterial thrombosis, HR 3.4
(95% CI: 3.0-3.8), 2.2 (95% CI: 2.0-2.3), and 2.1 (95% CI:
1.9-2.1), respectively. There were no significant differ-
ences in the effect of thrombosis on mortality for multiple
myeloma patients diagnosed before 2000 compared to
those diagnosed after this date (Table 1), according to sex
or to age of diagnosis (above/below 70 years of age).
These findings are important as they confirm that throm-
bosis in multiple myeloma is a serious complication,
increasing morbidity and even mortality, also in the era of
novel anti-tumor agents. 
Given that a multiple myeloma patient survived the first
six months following diagnosis (landmark analyses), early
VTE (within six months) was not associated with a higher
risk of death at one year (HR 1.4; 95% CI: 0.9-2.0), five
years (HR 1.1; 95% CI: 0.9-1.3), or ten years (HR 1.0; 95%
CI: 0.9-1.2) (Figure 1). In contrast, in a landmark analysis,
early arterial thrombosis was associated with a significant-
ly higher risk of death at one year (Hr 1.5; 95% CI: 1.1-
2.0), five years (HR 1.4; 95% CI: 1.2-1.6), and ten years
(HR 1.4; 95% CI: 1.2-1.6) (Figure 2). 
Thrombosis is a frequent complication in patients with
cancer and patients with various types of cancer have a
two times higher mortality if diagnosed with VTE and
three times higher during the first year.16 The occurrence
of DVT or pulmonary embolism in the general population
is associated with a decreased survival during the first six
months, and in cases of unprovoked VTE, up to three
years after diagnosis.11 Our study is the first to evaluate
the impact of VTE on survival in a large population-based
cohort of multiple myeloma patients. In accordance with
the findings from studies on other cancers,16 we show that
multiple myeloma patients with VTE have an almost 3-
fold higher risk of dying within one year after diagnosis of
thrombosis (compared to multiple myeloma patients
without a thrombosis) and 1.6-fold higher risk within the
first ten years. This is in contrast to the three previously
published retrospective clinical studies based on 668, 535,
s.y. Kristinsson et al.
1604 haematologica | 2012; 97(10)
Table 1. Risk of death among multiple myeloma patients with thrombosis com-
pared to those without.
HR for death HR for death HR for death 
within 1 year within 5 years within 10 years  
of MM diagnosis of MM diagnosis of MM diagnosis
(95% CI) (95% CI) (95% CI)
Any thrombosis 3.4 (3.0-3.8) 2.1 (2.0-2.2) 2.0 (1.9-2.2)
Any venous thrombosis 2.9 (2.4-3.5) 1.6 (1.5-1.8) 1.6 (1.4-1.7)
DVT only 1.9 (1.4-2.5) 1.4 (1.2-1.6) 1.4 (1.2-1.6)
PE only 4.7 (3.7-6.0) 2.1 (1.8-2.5) 1.9 (1.6-2.2)
Any arterial thrombosis 3.4 (3.0-3.8) 2.2 (2.0-2.3) 2.1 (1.9-2.1)
MI/angina only 3.0 (2.6-3.4) 2.0 (1.9-2.2) 2.0 (1.8-2.1)
Stroke/TIA only 4.1 (3.3-5.1) 2.3 (2.0-2.6) 2.1 (1.9-2.4)
Before 2000
Any arterial thrombosis 3.4 (3.0-3.9) 2.3 (2.1-2.5) 2.2 (2.0-2.3)
Any venous thrombosis 3.1 (2.5-3.8) 1.7 (1.5-1.9) 1.6 (1.5-1.8)
After 2000 NA
Any arterial thrombosis 3.6 (2.7-4.9) 2.7 (2.1-3.4) NA
Any venous thrombosis 1.9 (1.0-3.5) 1.6 (1.1-2.5) NA
HR: hazard ratios; CI: confidence interval;  DVT: deep-vein thrombosis; PE: pulmonary embolism;
MI: myocardial infarction; MM: multiple myeloma; TIA: transient ischemic attack.
and 353 patients, which reported that multiple myeloma
patients with VTE have a similar survival to those with-
out.12-14
There are some important differences between these
studies and ours. Firstly, we included all patients diag-
nosed with multiple myeloma in a whole population and
followed them for a long time period. Secondly, the other
studies are based on data from clinical trials, with some
patients excluded, for example, because of poor perform-
ance status and reduced cardiopulmonary function.12-13
Furthermore, two of the studies included relapsed/refrac-
tory patients and it is well known that these have a lower
risk of thrombosis compared to newly diagnosed
patients.17-20 Accordingly, we found the risk of death in
multiple myeloma patients with VTE to be highest during
the first year following diagnosis of the disease. Thirdly,
the patients in two clinical trials were younger than the
patients in our study (median age 57 and 63 years vs. 71
years, respectively).14,15 Age is a strong predictor for VTE
and this can, therefore, influence the outcome.9,21 Finally,
and perhaps most importantly, not all patients in our study
were treated with thalidomide or lenalidomide as these
agents were not available during the largest part of the
study period. We conclude that VTE in multiple myeloma
is a serious complication with a considerable impact on
overall survival.
Thrombosis and survival in MM 
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Figure 1. Survival among
multiple myeloma patients
with and without early
venous thrombembolism
(landmark analysis).
Figure 2. Survival among
multiple myeloma patients
with and without early arte-
rial thrombosis (landmark
analysis).
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Interestingly, based on landmark analyses, survival
rates for multiple myeloma patients with an early VTE
who survived their first six months were similar to multi-
ple myeloma patients without VTE during the first six
months. Based on data from the Total Therapy 2 study,
95% of the VTEs were diagnosed within the first 12
months.12 In their study into the impact of VTE on sur-
vival, a 12-month landmark analysis was used and early
mortality was, therefore, not evaluated. In the study
based on data on relapsed/refractory multiple myeloma
patients treated with lenalidomide, 96.7% of thrombotic
events occurred in the first 12 months from start of treat-
ment, and a 6-month landmark was used.15 Taken togeth-
er, VTE is associated with higher mortality; however, the
findings from our study, as well as those from the previ-
ously published studies, show that those patients who
survive a VTE within the first 6-12 months do not seem
to have a poorer survival. There are several potential
mechanisms to explain these findings. Firstly, it has been
suggested that the occurrence of thrombosis is partly
related to the response to the treatment, and that patients
who respond have an increased risk of VTE. Furthermore,
the impact of low-molecular weight heparin (LMWH) on
survival needs to be evaluated as this is usually used to
treat VTE, and has been shown to have anti-tumoral
activity.22 In addition, it is possible that multiple myeloma
patients who survive their early thrombosis are in some
way healthier than those who do not, introducing a bias
contributing to an observed improvement in long-term
survival.
This is the first study to our knowledge to evaluate the
impact of arterial thrombosis on survival in multiple
myeloma patients. Overall, diagnosis of arterial thrombo-
sis was associated with a 3.4-fold higher risk of death
within one year following multiple myeloma (compared
to multiple myeloma patients without an arterial event)
and a 2.1-fold risk within the first ten years. In contrast to
VTE, we found early arterial thrombosis to be associated
with a higher risk of death also in those surviving their
first six months. This confirms that arterial thrombosis
(myocardial infarction, angina, stroke, and TIA) is a very
serious complication in multiple myeloma patients and is
associated with immediate morbidity, and early and long-
term mortality.23-24 One explanation might also be that
patients with arterial thrombosis are treated as aggressive-
ly as other multiple myeloma patients.
Our study has several strengths, including its large size
and the application of high-quality data from Sweden, a
country with a stable population who had access to stan-
dardized medical care during the entire study period. In
our study, we used a register-based cohort design that
ensured a population-based setting and the generalizabili-
ty of our findings. In a recent validation study, we reported
that ascertainment and diagnostic accuracy for multiple
myeloma is very high in Sweden (>90-95%).15 Study limi-
tations are the lack of detailed clinical data, including
information on anti-multiple myeloma therapy, subtype
of multiple myeloma, underlying diseases and risk factors
for thrombosis. Another limitation is the potential inaccu-
racy and lack of independent validation of thrombotic
diagnosis obtained from the centralized Patient Registry.
In summary, in this large population-based study based
on over 9,000 multiple myeloma patients, we found, in
contrast to previously published studies, that the occur-
rence of any thrombosis was associated with a significant-
ly poorer survival. Multiple myeloma patients with an
early arterial or venous thrombosis had a higher risk of
death than patients without. However, multiple myeloma
patients with an early VTE who survived their first six
months had similar survival rates to those without VTE.
Therefore, our findings confirm that thrombosis in multi-
ple myeloma patients is a serious complication, and that it
increases mortality, also in the era of novel agents. It is
important to investigate whether more effective preven-
tion of thromboembolism can improve the survival of
multiple myeloma patients.
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